- Home
- GRX vs SLS Comparison
GRX vs SLS Comparison
Compare GRX & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRX
- SLS
- Stock Information
- Founded
- GRX 2007
- SLS 2012
- Country
- GRX United States
- SLS United States
- Employees
- GRX N/A
- SLS N/A
- Industry
- GRX Finance/Investors Services
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- GRX Finance
- SLS Health Care
- Exchange
- GRX Nasdaq
- SLS Nasdaq
- Market Cap
- GRX 148.5M
- SLS 169.6M
- IPO Year
- GRX N/A
- SLS N/A
- Fundamental
- Price
- GRX $9.31
- SLS $1.54
- Analyst Decision
- GRX
- SLS
- Analyst Count
- GRX 0
- SLS 0
- Target Price
- GRX N/A
- SLS N/A
- AVG Volume (30 Days)
- GRX 39.7K
- SLS 2.5M
- Earning Date
- GRX 01-01-0001
- SLS 08-12-2025
- Dividend Yield
- GRX 5.98%
- SLS N/A
- EPS Growth
- GRX N/A
- SLS N/A
- EPS
- GRX 0.26
- SLS N/A
- Revenue
- GRX N/A
- SLS N/A
- Revenue This Year
- GRX N/A
- SLS N/A
- Revenue Next Year
- GRX N/A
- SLS N/A
- P/E Ratio
- GRX $38.50
- SLS N/A
- Revenue Growth
- GRX N/A
- SLS N/A
- 52 Week Low
- GRX $7.73
- SLS $0.77
- 52 Week High
- GRX $10.40
- SLS $2.12
- Technical
- Relative Strength Index (RSI)
- GRX 38.70
- SLS 45.96
- Support Level
- GRX $9.26
- SLS $1.47
- Resistance Level
- GRX $9.74
- SLS $1.73
- Average True Range (ATR)
- GRX 0.10
- SLS 0.11
- MACD
- GRX -0.03
- SLS -0.02
- Stochastic Oscillator
- GRX 10.42
- SLS 19.44
About GRX The Gabelli Healthcare & Wellness Trust of Beneficial Interest
Gabelli Healthcare & WellnessRx Trust operates as a diversified closed-end management investment company. The investment objective of the fund is the long-term growth of capital. The fund invests at least its assets in equity securities and income-producing securities of domestic and foreign companies in the healthcare and wellness industries. It invests in various sectors, of which Health Care Providers & Services, Food, Health Care Equipment and Supplies, and Pharmaceuticals account for the majority of the weightage.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.